KAHR Medical Ltd.
Sector: Biotechnology - Therapeutics
Medical Field: Autoimmune Diseases
Technological Field: Immune Modulators
Year Established: 2007
The mission at KAHR Medical is to develop novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. The company's drug development pipeline is built around 'Dual Signaling Proteins (DSP)' - a unique class of novel therapeutic agents that possess two functional ends. The DSP technology is divided into two proprietary platforms; the DSP-Hexamers and the DSP-Clusters, each covering hundreds of drug candidates. KAHR operates two active drug-development programs, KAHR-101 and KAHR-102, each representing proof-of-concept for its proprietary platforms.
The pre-clinical file for KAHR-102 was recently submitted to the Israeli regulatory authorities and the first clinical trial for the treatment of lymphatic cancer is expected to initiate in mid-2016 in Israel